Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-12-10

Clinical Trial Update: Erlotinib in Treating Patients With Stage III or Stage IV Pancreatic Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating erlotinib for stage III or stage IV pancreatic cancer was terminated; results were posted on 2014-12-10.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ERLOTINIB (Erlotinib)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Pancreatic Cancer | Phase 2 | Status: TERMINATED | Results posted: 2014-12-10